Clinical Trials Browser

Expanded_access × sugemalimab × Clear all

NCT05131438 2023-03-27

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

No longer available

Recurrence, Lymphoma, Extranodal NK-T-Cell